Why should the average busy intensivist take the time to read a seemingly obscure article on risk factors for imipenem resistance in Pseudomonas aeruginosa isolates from far away Brazil 1 ? It is not even a randomised clinical trial! There are, however, some important take-home messages.
The first and most obvious is that carbapenem resistance is increasing and poses a significant risk to our patients. The lack of new agents effective against resistant gram-negative organisms has been highlighted elsewhere 2 . Carbapenem resistance due to a variety of mechanisms has been reported in Australia 3 . Overseas, Klebsiella pneumoniae with carbapenemases (termed KPC) have caused substantial outbreaks in New York and a nationwide outbreak in Israel with substantial morbidity and mortality 4 . A plasmid associated metallo-beta lactamase termed NDM (New Dehli metallo beta-lactamase) has been identified in the United Kingdom in individuals returning from the subcontinent and the plasmid appears to spread efficiently 5 . That virulent resistant organisms may be imported from overseas should be evident from the recent reports of hypervirulent Clostridium difficile in Melbourne.
The second point to consider is the complexity of resistance mechanisms in gram-negative bacteria, and the sometimes confusing relationships with antimicrobials. The article in this journal illustrates this conundrum -surely carbapenem use would be the major driver for carbapenem resistance? It appears not, and mechanisms of resistance in gramnegative organisms have degrees of sophistication that are bewildering.
The defining feature in gram-negative bacteria is the presence of the outer lipid membrane. Within this layer the bacteria houses porins, which allow the organism to regulate the entry of many substances. Mutations to these porins can decrease the access of antibiotics to their active sites; in the case of carbapenems, to the penicillin binding proteins, which are embedded in the inner lipid bilayer. The presence of the outer lipid membrane also creates a space between the two layers -the periplasmic space. Within this domain the bacteria secrete a myriad of enzymes, which held in by the outer membrane, remain in high concentration.
Finally spanning both membranes, gram-negative bacteria have efflux pumps that remove unwanted substances from the cytoplasm. Efflux pumps can have a broad spectrum of substances removed and substrates which induce them. For example, the MexCD-OprJ multidrug efflux system of Pseudomonas aeruginosa can be induced by chlorhexidine. What you use to clean the patient's skin may be inducing resistance to the antibiotic you will need to use in a few days' time 6 .
Gram-negative organisms are also promiscuous beasts that readily swap genetic elements such as plasmids across different genera. These plasmids contain a variety of genes coding for expanding families of beta lactamases and other resistance mechanisms which readily slot into the organism's chromosome using gene cassettes. The imipenem resistance mediated by an AMP-C enzyme brought in to your intensive care unit in a Klebsiella pnemoniae can reappear in an Escherichia coli in the patient next door, and may be further induced by the clavulanic acid in the beta lactam/lactamase combination you use as your first line therapy 7 . These three mechanisms also combine such that while one individual mechanism may not lead to phenotypic resistance, in combination resistance may be achieved.
These mechanisms contrast starkly with grampositive bacteria, which, lacking an outer membrane, rely largely (but not exclusively) on altering the affinity of the target site to manifest resistance to antimicrobials. For example, Streptococcus pneumoniae does not produce a single beta-lactamase but relies on changes in affinity of its penicillin binding proteins to manifest penicillin resistance.
The final point to consider is the methodology used in the paper. One of the authors of this article, Dr Sergio Wey, was the lead author in a landmark paper which elegantly defined the attributable morbidity and mortality of candidaemia using a very detailed case control approach. Not all that we learn comes from randomised controlled trials 8 .
What is the busy intensivist to do with such knowledge? The best approach would appear to be practice hand hygiene with obsessive vigor, limit the duration of antibiotics to the absolute minimum, remove all foreign bodies that breach natural Anaesth Intensive Care 2010; 38: 987-988 Editorials Antimicrobial resistance and antibiotic use defences when no longer required, and lobby for a multidisciplinary approach to managing antibiotic stewardship, infection control and microbiology liaison. An appreciation of the pharmacokinetics and pharmacodynamics of antimicrobials in the critically ill is also essential. A national approach to surveillance of antimicrobial resistance and antibiotic use with access to rapid recognition of mechanisms of resistance remains a distant but important goal. It is time for the 'average busy intensivist' to take a leadership role in antibiotic resistance and roll up the sleeves (literally) to tackle the issue.
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